Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use

Breast cancer is a complex disease with heterogeneous presentation and clinical course. The last decade has witnessed the development, commercialization, and increasing use of multigene assays, designed to support physicians and patients in clinical decision making in early-stage breast cancer. These include Oncotype DX®, MammaPrint®, and Prosigna™ assays. The assays differ in the technological platforms used for assessment of gene expression, in the number of genes and in the specific genes that are being tested, in the patient populations used for their development and validation, and in their clinical utility. This review focuses on these three commercialized assays, their development, validation, and clinical utility. The review also addresses ongoing prospective trials investigating these assays and health-economic considerations relating to their use.

[1]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[3]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[4]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[5]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[6]  Thomas J. Smith,et al.  Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer , 2005, ACP journal club.

[7]  Richard Simon,et al.  Roadmap for developing and validating therapeutically relevant genomic classifiers. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[9]  Gary H Lyman,et al.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. , 2005, The American journal of managed care.

[10]  Roman Rouzier,et al.  Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Shak,et al.  A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients , 2006, Breast Cancer Research.

[13]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[14]  J. Hornberger,et al.  Impact of a 21‐gene RT‐PCR assay on treatment decisions in early‐stage breast cancer , 2007, Cancer.

[15]  A. Cohn,et al.  Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. , 2007, Journal of oncology practice.

[16]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Andreas Makris,et al.  Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients , 2008, Breast Cancer Research and Treatment.

[18]  Wim H van Harten,et al.  Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). , 2007, The Lancet. Oncology.

[19]  A. Glas,et al.  The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study , 2009, Breast Cancer Research and Treatment.

[20]  A. Hart,et al.  Validation of 70-gene prognosis signature in node-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[21]  Robert Gray,et al.  Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Gelber,et al.  Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.

[23]  P. Tartter,et al.  Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? , 2008, American journal of surgery.

[24]  A. 510k.  510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY , 2008 .

[25]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. J. Veer,et al.  Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature , 2010, Annals of Surgical Oncology.

[27]  D. Hayes,et al.  Extended follow-up results from a prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, satisfaction, and anxiety. , 2009 .

[28]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[29]  B. O'Leary,et al.  PCN12 COST-EFFECTIVENESS OF THE ONCOTYPE DX® ASSAY IN AUSTRALIA: AN EXPLORATORY ANALYSIS , 2010 .

[30]  M. J. van de Vijver,et al.  The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  T. Yamanaka,et al.  Clinical significance of the 21‐gene signature (Oncotype DX) in hormone receptor‐positive early stage primary breast cancer in the Japanese population , 2010, Cancer.

[32]  V. Band,et al.  Histological, molecular and functional subtypes of breast cancers , 2010, Cancer biology & therapy.

[33]  D. Hayes,et al.  Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[35]  T. Yamanaka,et al.  Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) , 2011, Breast Cancer Research and Treatment.

[36]  Jack Cuzick,et al.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Michael Hauptmann,et al.  The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer , 2010, Breast Cancer Research and Treatment.

[38]  E. Chen,et al.  Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer. , 2010, The American journal of managed care.

[39]  S. Verma,et al.  Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. , 2010, The oncologist.

[40]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[41]  Ariel Hammerman,et al.  Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[42]  E. Rutgers,et al.  The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. , 2011, European journal of cancer.

[43]  M. Joore,et al.  Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance , 2011, Breast Cancer Research and Treatment.

[44]  J. Hornberger,et al.  P215A Cost–benefit analysis of a 21-gene recurrence score for early stage breast cancer in Singapore , 2011 .

[45]  N. Sion-Vardy,et al.  The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  J. Hornberger,et al.  P1-10-04: Cost-Utility of the 21-Gene Breast Cancer Assay (Oncotype DX®) in the Irish Healthcare Setting. , 2011 .

[47]  I. Láng,et al.  P215B Evaluation of the cost-effectiveness of Oncotype-DX® multigene assay in Hungary , 2011 .

[48]  J. Hainsworth,et al.  P5-13-09: Correlation of Oncotype DX Recurrence Scores with Pathologic Response Following Neoadjuvant Ixabepilone and Cyclophosphamide in Patients with HER2−Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial. , 2011 .

[49]  D. Dabbs,et al.  High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Broder,et al.  Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. , 2011, Journal of oncology practice.

[51]  B. Pham,et al.  PCN72 GENE EXPRESSION PROFILING FOR GUIDING ADJUVANT CHEMOTHERAPY DECISIONS IN WOMEN WITH EARLY BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS OF 1000 STRATEGIES FOR THE PROVISION OF ADJUVANT! ONLINE, ONCOTYPE DX AND CHEMOTHERAPY , 2011 .

[52]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  Mark T. W. Ebbert,et al.  PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers , 2012, BMC Medical Genomics.

[54]  D. Rayson,et al.  Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer , 2012, Breast Cancer Research and Treatment.

[55]  A. Roquancourt,et al.  Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France. , 2012 .

[56]  R. Rouzier,et al.  PMD51 Cost-Effectiveness of a Predictive Test of the Benefit of Chemotherapy , 2012 .

[57]  F. Rojo,et al.  Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  T. Julian,et al.  Abstract S1-10: Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28 , 2012 .

[59]  C. Villarreal-Garza,et al.  A Study of the Impact of the 21-Gene Breast Cancer Assay on the Use of Adjuvant Chemotherapy in Women With Breast Cancer in a Mexican Public Hospital , 2012 .

[60]  R. Rouzier,et al.  [Cost-effectiveness of a chemotherapy predictive test]. , 2012, Bulletin du cancer.

[61]  A. Issa,et al.  Cost effectiveness of gene expression profiling for early stage breast cancer , 2012, Cancer.

[62]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.

[63]  Harald Frick,et al.  How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists , 2012, PloS one.

[64]  R. Rouzier,et al.  Analyse coût-efficacité d’un test prédictif de la chimiothérapie dans le cancer du sein (Oncotype DX®) en France , 2012 .

[65]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[66]  Mark T. W. Ebbert,et al.  Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer. , 2012, The oncologist.

[67]  G. Bertelli,et al.  A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK , 2013, British Journal of Cancer.

[68]  M. Rezai,et al.  Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting , 2013, Journal of medical economics.

[69]  K. Gelmon,et al.  A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer. , 2013, European journal of cancer.

[70]  Jack Cuzick,et al.  Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[72]  M. Rezai,et al.  The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  S. Cawthorn,et al.  A prospective multi-centre study of the impact of Oncotype DX (R) on adjuvant treatment decisions in patients in the UK with estrogen receptor positive early breast cancer , 2013 .

[74]  S. Klang,et al.  The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients , 2013, Breast Cancer Research and Treatment.

[75]  R. Greil,et al.  Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. , 2013 .

[76]  J. Wesseling,et al.  A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study , 2013, International journal of cancer.

[77]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[79]  Josh J. Carlson,et al.  The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis , 2013, Breast Cancer Research and Treatment.

[80]  C. Yoshizawa,et al.  The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer , 2013, The Medical journal of Australia.

[81]  R. Greil,et al.  Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  A. Glas,et al.  MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. , 2014, The Journal of molecular diagnostics : JMD.

[83]  R. Greil,et al.  The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer , 2014, Clinical Cancer Research.

[84]  Seigo Nakamura,et al.  Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer. , 2014, Clinical breast cancer.

[85]  E. Rutgers,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  C. Villarreal-Garza,et al.  A study of the impact of the 21‐gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital , 2015, Journal of surgical oncology.